This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CoDiagnostics (CODX) delivered earnings and revenue surprises of 26.47% and 564.25%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
GeneDx Holdings Corp. (WGS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
GENEDX HOLDINGS (WGS) delivered earnings and revenue surprises of 57.69% and 19.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 1.63% and 0.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Elevance Health (ELV) Beats Q1 Earnings Estimates
by Zacks Equity Research
Elevance Health (ELV) delivered earnings and revenue surprises of 0.95% and 0.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 0.58% and 0.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of -29.17% and 73.60%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Sharecare, Inc. (SHCR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sharecare, Inc. (SHCR) delivered earnings and revenue surprises of 0% and 0.21%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of 13.04% and 45.27%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of -57.14% and 3.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ModivCare (MODV) Misses Q1 Earnings Estimates
by Zacks Equity Research
ModivCare (MODV) delivered earnings and revenue surprises of -4.05% and 6.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of -113.33% and 74.53%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
DocGo Inc. (DCGO) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
DocGo Inc. (DCGO) delivered earnings and revenue surprises of 120% and 4.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
CoDiagnostics, Inc. (CODX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 33.33% and 24.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
CoDiagnostics, Inc. (CODX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of -166.67% and 75.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
CoDiagnostics, Inc. (CODX) Surges 5.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CoDiagnostics, Inc. (CODX) Surges 5.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Do Options Traders Know Something About CoDiagnostics (CODX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to CoDiagnostics (CODX) stock based on the movements in the options market lately.
CoDiagnostics, Inc. (CODX) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 44.44% and 6.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Why the Earnings Surprise Streak Could Continue for CoDiagnostics, Inc. (CODX)
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CoDiagnostics, Inc. (CODX) Q4 Earnings Beat Estimates
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 66.67% and 5.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
HealthEquity (HQY) Q4 Earnings Miss Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of -4.76% and 2.02%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
CoDiagnostics, Inc. (CODX) Surges 13.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Biodesix, Inc. (BDSX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of 2% and 1.45%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Assure Holdings Corp. (IONM): Can Its 7.3% Jump Turn into More Strength?
by Zacks Equity Research
Assure Holdings Corp. (IONM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Should Value Investors Buy These Medical Stocks?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.